FDA Okays J&J's RYBREVANT For Advanced Non-Small Cell Lung Cancer In Combination With Chemotherapy
20/9 02:47
(RTTNews) - Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration approved RYBREVANT (amivantamab-vmjw) in combination with standard of care chemotherapy (carboplatin and pemetrexed) for the treatment of adult patients with locally advanced or metastatic no...